Drug developer Targacept (TRGT +0.6%) is down 82% from its 52-week high, but MKM Partners thinks...

|By:, SA News Editor

Drug developer Targacept (TRGT +0.6%) is down 82% from its 52-week high, but MKM Partners thinks the stock could triple. The firm says TRGT has at least one thing going for it that most other biopharmas don't: multiple trials for multiple drugs with multiple indications. And even if none of them pan out, its cash balance makes it an attractive long-term play.